TABLE 1.

Hematologic toxicities and antiangiogenic adverse events among patients with advanced non‐small‐cell lung cancer treated with nivolumab and chemotherapy

	Arm A N = 6		Arm B N = 6		Arm C N = 6		Arm D N = 6
Regimen	Cisplatin Gemcitabine Nivolumab		Cisplatin Pemetrexed Nivolumab		Carboplatin Paclitaxel Bevacizumab Nivolumab		Docetaxel Nivolumab
Adverse event	Any grade	Grade 3‐4	Any grade	Grade 3‐4	Any grade	Grade 3‐4	Any grade	Grade 3‐4
Hematologic toxicities
White blood cell count decreased	6 (100)	0 (0.0)	5 (83.3)	0 (0.0)	6 (100)	3 (50.0)	6 (100)	5 (83.3)
Neutrophil count decreased	6 (100)	1 (16.7)	5 (83.3)	1 (16.7)	6 (100)	6 (100)	6 (100)	6 (100)
Lymphocyte count decreased	4 (66.7)	0 (0.0)	1 (16.7)	0 (0.0)	4 (66.7)	1 (16.7)	5 (83.3)	3 (50.0)
Anemia	6 (100)	0 (0.0)	4 (66.7)	0 (0.0)	4 (66.7)	1 (16.7)	4 (66.7)	0 (0.0)
Platelet count decreased	6 (100)	0 (0.0)	3 (50.0)	0 (0.0)	6 (100)	2 (33.3)	0 (0.0)	0 (0.0)
Antiangiogenic adverse events
Hypertension	1 (16.7)	0 (0.0)	1 (16.7)	1 (16.7)	4 (66.7)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	0 (0.0)	1 (16.7)	0 (0.0)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (66.7)	0 (0.0)	0 (0.0)	0 (0.0)

Data are presented as n (%), with n referring to the number of events.